Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares Outstanding
Ratios

Oncology Institute (TOI) Depreciation & Amortization (IS) (2021 - 2025)

Oncology Institute's Depreciation & Amortization (IS) history spans 5 years, with the latest figure at $1.6 million for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (IS) fell 4.39% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $6.9 million, up 10.45%, while the annual FY2025 figure was $6.9 million, 10.45% up from the prior year.
  • Depreciation & Amortization (IS) reached $1.6 million in Q4 2025 per TOI's latest filing, down from $1.7 million in the prior quarter.
  • In the past five years, Depreciation & Amortization (IS) ranged from a high of $1.8 million in Q2 2025 to a low of $777000.0 in Q1 2021.
  • Average Depreciation & Amortization (IS) over 5 years is $1.3 million, with a median of $1.4 million recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (IS): skyrocketed 49.74% in 2023, then decreased 7.36% in 2024.
  • A 5-year view of Depreciation & Amortization (IS) shows it stood at $920000.0 in 2021, then grew by 29.57% to $1.2 million in 2022, then soared by 32.3% to $1.6 million in 2023, then rose by 8.24% to $1.7 million in 2024, then dropped by 4.39% to $1.6 million in 2025.
  • Per Business Quant, the three most recent readings for TOI's Depreciation & Amortization (IS) are $1.6 million (Q4 2025), $1.7 million (Q3 2025), and $1.8 million (Q2 2025).